No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
JNJ240705P148000
- 2.22
- +0.42+23.33%
15min DelayClose Jul 2 16:00 ET
2.22High2.19Low
2.19Open1.80Pre Close2 Volume543 Open Interest148.00Strike Price441.00Turnover13.11%IV0.17%PremiumJul 5, 2024Expiry Date1.97Intrinsic Value100Multiplier2DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type-0.8845Delta0.1359Gamma71.94Leverage Ratio-0.0418Theta-0.0059Rho-63.63Eff Leverage0.0240Vega
Intraday
- 5D
- Daily
News
Johnson & Johnson (JNJ.US) / Legend Biotech (LEGN.US) CAR-T therapy has achieved positive results in phase III.
According to the news from the Securities Times app, on July 3, Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) jointly announced the positive results of the planned second interim analysis of the Phase 3 CARTITUDE-4 study. The study evaluated the chimeric antigen receptor (CAR) T cell therapy Carvykti jointly developed by the two companies, compared to standard therapy, for the treatment of patients with relapsed or refractory multiple myeloma (MM) who are resistant to lenalidomide after 1st-line treatment. The interim analysis showed that compared with standard therapy, patients treated with Carvykti had a longer overall survival.
Express News | Health Canada Authorizes Rybrevant® (Amivantamab) in Combination With Carboplatin and Pemetrexed as the Only Targeted First-Line Treatment Approved for Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations
China International Capital Corporation: Colored contact lenses promote demand upgrade, and manufacturing business enters the golden development period.
Terminal demand upgrades, technological innovation, and changes in the market landscape will drive rapid development in the domestic industry chain. Contact lenses and colored contact lenses will usher in new development opportunities and are expected to continue to maintain a strong growth trend in the next few years.
Express News | Johnson & Johnson has received approval from the US Food and Drug Administration and the European Commission for SIRTURO (bedaquiline), a pharmaceutical.
Express News | Johnson & Johnson Receives Approval From U.S. FDA and European Commission for Sirturo® (Bedaquiline)
JNJ Should Rally Soon or See 3 Swings Higher at Least
Johnson & Johnson (JNJ) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue.